<DOC>
	<DOCNO>NCT01337791</DOCNO>
	<brief_summary>Telbivudine reduce DNA normalizes alanine aminotransferase level ( ALT ) chronic hepatitis B patient adverse effect , use pregnancy explore . In open-label , prospective study second trimester post-partum week 28 . This trial study efficacy , safety tolerability Telbivudine HBeAg Positive Chronic Hepatitis B Pregnant Women high level serum HBV DNA elevate alanine aminotransferase level .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Telbivudine HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>age 2040 year gestational age 1230 week serum HBsAg HBeAg positivity HBV DNA level &gt; 6log10 copies/mL ALT &gt; 1x ULN ( 40 IU/mL ) &lt; 10x ULN . coinfection hepatitis A , C , D , E HIV evidence hepatocellular carcinoma ; decompensated liver disease significant renal , cardiovascular , respiratory neurological comorbidity concurrent treatment immunemodulators , cytotoxic drug , steroid clinical sign threaten miscarriage early pregnancy evidence fetal deformity 3dimensional ultrasound examination biological father child CHB</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>hepatitis B virus</keyword>
	<keyword>perinatal transmission</keyword>
	<keyword>Telbivudine</keyword>
</DOC>